
Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission.Â

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, discusses cessation of chronic myeloid leukemia (CML) treatment for therapy-free remission.Â

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, explains why some patients with CML don't adhere to their medication.

Published: February 25th 2015 | Updated:

Published: December 31st 2015 | Updated: